文献速递血栓与止血

抑制纤溶不能改善血友病啮齿类动物非黏膜静脉损伤模型的出血或rFVIIa/rFVIII治疗效果

Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
PubMed 文献 · J Thromb Haemost · 2018-06-21

本研究在血友病小鼠和大鼠的非黏膜尾静脉横断出血模型中,通过基因敲除或药物(氨甲环酸)抑制纤溶,观察出血及对因子治疗的反应。结果显示全身抑制纤溶在体内未改善出血表型或rFVIIa/rFVIII疗效,体外试验的有益效果未能在体内证实。

要点

  • 血友病A非黏膜出血表型似乎主要不受纤溶影响。
  • 全身氨甲环酸在血友病大鼠体外试验中的有益效果未能在大鼠体内证实。
  • 静脉氨甲环酸或先天敲除纤溶酶原/组织型纤溶酶原激活物基因均未显著改善小鼠尾静脉横断出血表型或因子治疗反应。

核心结论

  • 抑制纤溶不能有效限制血友病A啮齿类动物非黏膜组织的尾静脉横断出血表型。

研究设计与样本

  • 在血友病啮齿类动物中采用高灵敏度尾静脉横断模型,结合基因或药物(氨甲环酸)抑制纤溶系统。
  • 小鼠中联合诱导型和先天型血友病模型与基因或药物(氨甲环酸)抑制纤溶。
  • 大鼠中尾静脉出血后对同一动物进行全血旋转血栓弹力评估,以判断该试验的预测价值。

主要发现

  • 血友病大鼠体外观察到的全身氨甲环酸有益效果未能在体内证实。
  • 静脉给予氨甲环酸或先天敲除纤溶酶原或组织型纤溶酶原激活物基因,均未显著改善血友病小鼠的尾静脉横断出血表型或对因子治疗的反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials The efficacy of systemic antifibrinolytics for hemophilic non-mucosal bleeding is undetermined. The effect of systemically inhibiting fibrinolysis in hemophilic mice and rats was explored. Neither bleeding nor the response to factor treatment was improved after inhibiting fibrinolysis. The non-mucosal bleeding phenotype in hemophilia A appears largely unaffected by fibrinolysis. SUMMARY: Background Fibrinolysis may exacerbate bleeding in patients with hemophilia A (HA). Accordingly, antifibrinolytics have been used to help maintain hemostatic control. Although antifibrinolytic drugs have been proven to be effective in the treatment of mucosal bleeds in the oral cavity, their efficacy in non-mucosal tissues remain an open question of significant clinical interest. Objective To determine whether inhibiting fibrinolysis improves the outcome in non-mucosal hemophilic tail vein transection (TVT) bleeding models, and to determine whether a standard ex vivo clotting/fibrinolysis assay can be used as a predictive surrogate for in vivo efficacy. Methods A highly sensitive TVT model was employed in hemophilic rodents with a suppressed fibrinolytic system to examine the effect of inhibiting fibrinolysis on bleeding in non-mucosal tissue. In mice, induced and congenital hemophilia models were combined with fibrinolytic attenuation achieved either genetically or pharmacologically (tranexamic acid [TXA]). In hemophilic rats, tail bleeding was followed by whole blood rotational thromboelastometry evaluation of the same animals to gauge the predictive value of such assays. Results The beneficial effect of systemic TXA therapy observed ex vivo could not be confirmed in vivo in hemophilic rats. Furthermore, neither intravenously administered TXA nor congenital knockout of the fibrinolytic genes encoding plasminogen or tissue-type plasminogen activator markedly improved the TVT bleeding phenotype or response to factor therapy in hemophilic mice. Conclusions The findings here suggest that inhibition of fibrinolysis is not effective in limiting the TVT bleeding phenotype of HA rodents in non-mucosal tissues.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Stagaard R, Flick MJ, Bojko B, et al. Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents. J Thromb Haemost. 2018. PMID: 29758126. doi:10.1111/jth.14148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。